JP6158801B2 - 代謝経路を変調させるための組成物および方法 - Google Patents

代謝経路を変調させるための組成物および方法 Download PDF

Info

Publication number
JP6158801B2
JP6158801B2 JP2014520397A JP2014520397A JP6158801B2 JP 6158801 B2 JP6158801 B2 JP 6158801B2 JP 2014520397 A JP2014520397 A JP 2014520397A JP 2014520397 A JP2014520397 A JP 2014520397A JP 6158801 B2 JP6158801 B2 JP 6158801B2
Authority
JP
Japan
Prior art keywords
composition
resveratrol
subject
leucine
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014520397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520864A5 (enExample
JP2014520864A (ja
Inventor
マイケル ジメル，
マイケル ジメル，
イー． ダグラス ザ セカンド グリンドスタッフ，
イー． ダグラス ザ セカンド グリンドスタッフ，
アンチェ ブルックバウアー，
アンチェ ブルックバウアー，
Original Assignee
ニューサート サイエンシーズ， インコーポレイテッド
ニューサート サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューサート サイエンシーズ， インコーポレイテッド, ニューサート サイエンシーズ， インコーポレイテッド filed Critical ニューサート サイエンシーズ， インコーポレイテッド
Publication of JP2014520864A publication Critical patent/JP2014520864A/ja
Publication of JP2014520864A5 publication Critical patent/JP2014520864A5/ja
Application granted granted Critical
Publication of JP6158801B2 publication Critical patent/JP6158801B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
JP2014520397A 2011-07-15 2012-07-13 代謝経路を変調させるための組成物および方法 Active JP6158801B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201161508139P 2011-07-15 2011-07-15
US61/508,139 2011-07-15
US201261636598P 2012-04-20 2012-04-20
US201261636605P 2012-04-20 2012-04-20
US201261636608P 2012-04-20 2012-04-20
US201261636597P 2012-04-20 2012-04-20
US201261636610P 2012-04-20 2012-04-20
US201261636603P 2012-04-20 2012-04-20
US61/636,608 2012-04-20
US61/636,610 2012-04-20
US61/636,605 2012-04-20
US61/636,598 2012-04-20
US61/636,597 2012-04-20
US61/636,603 2012-04-20
PCT/US2012/046814 WO2013012760A1 (en) 2011-07-15 2012-07-13 Compositions and methods for modulating metabolic pathways

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017113544A Division JP2017160258A (ja) 2011-07-15 2017-06-08 代謝経路を変調させるための組成物および方法

Publications (3)

Publication Number Publication Date
JP2014520864A JP2014520864A (ja) 2014-08-25
JP2014520864A5 JP2014520864A5 (enExample) 2015-09-03
JP6158801B2 true JP6158801B2 (ja) 2017-07-05

Family

ID=47519040

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014520397A Active JP6158801B2 (ja) 2011-07-15 2012-07-13 代謝経路を変調させるための組成物および方法
JP2017113544A Pending JP2017160258A (ja) 2011-07-15 2017-06-08 代謝経路を変調させるための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017113544A Pending JP2017160258A (ja) 2011-07-15 2017-06-08 代謝経路を変調させるための組成物および方法

Country Status (16)

Country Link
US (9) US8617886B2 (enExample)
EP (2) EP3466418A1 (enExample)
JP (2) JP6158801B2 (enExample)
KR (1) KR20140054066A (enExample)
CN (3) CN103889411B (enExample)
AU (2) AU2012284267B2 (enExample)
BR (1) BR112014000895A2 (enExample)
CA (1) CA2841748C (enExample)
HK (2) HK1251146A1 (enExample)
IL (1) IL230467B (enExample)
MX (1) MX2014000419A (enExample)
PH (1) PH12014500198A1 (enExample)
RU (2) RU2017129378A (enExample)
SG (1) SG10201609673QA (enExample)
WO (1) WO2013012760A1 (enExample)
ZA (1) ZA201400553B (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3466418A1 (en) 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
EP2875359A4 (en) * 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLISM SYNDROME DISEASES
CN108452311A (zh) 2012-11-13 2018-08-28 纽斯尔特科学公司 用于增强能量代谢的组合物和方法
WO2014113404A1 (en) 2013-01-15 2014-07-24 Nusirt Sciences, Inc. Treating pulmonary conditions
CA2895914C (en) * 2013-01-18 2023-06-20 Procell Sprl Urolithin b with testosterone, leucine and/or creatine for muscle growth
MX370090B (es) 2013-02-01 2019-10-25 Centro De Investig En Alimentacion Y Desarrollo A C Un método y un sistema para el tratamiento integral de aguas residuales de una industria del maíz.
CN105188695A (zh) * 2013-03-14 2015-12-23 雅培制药有限公司 与长期体力活动不足有关的胰岛素抗性的治疗
WO2014152016A1 (en) 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
AU2014238377A1 (en) * 2013-03-15 2015-09-10 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators
CA2923705C (en) 2013-10-09 2024-05-14 Nestec S.A. Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome
US9138453B2 (en) 2013-10-14 2015-09-22 Biomarker Pharmaceuticals, Inc. Nutrient combinations for affecting an aging process
WO2015094772A1 (en) * 2013-12-18 2015-06-25 Abbott Laboratories Methods for increasing skeletal muscle protein synthesis using green tea extract
MX2016011063A (es) * 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
EP3122348B1 (en) 2014-03-27 2020-05-27 Winterfield, Roland, W. Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
JP6309343B2 (ja) * 2014-05-21 2018-04-11 協和発酵バイオ株式会社 ３−ヒドロキシ−３−メチル酪酸カルシウム含有錠剤およびその製造方法
WO2016049236A1 (en) * 2014-09-24 2016-03-31 Nusirt Sciences, Inc. Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
ITMI20141843A1 (it) * 2014-10-27 2016-04-27 Giovannini Luca Associazioni sinergiche stimolanti l¿espressione di sirtuina 1
CN107405503A (zh) * 2014-12-19 2017-11-28 光环生命科学有限公司 鞣花酸二水合物在药物制剂中调节血糖水平的用途
EP3244851B1 (en) 2015-01-12 2024-10-16 Bausch + Lomb Ireland Limited Micro-droplet delivery device
AU2016227767A1 (en) * 2015-03-03 2017-07-27 Société des Produits Nestlé S.A. Compound use in promoting energy expenditure
CN104771327B (zh) * 2015-03-11 2017-09-12 广州健坤生物科技有限公司 一种具有激活hsf‑1转录功能的组合物及其用途
WO2016151372A1 (en) * 2015-03-21 2016-09-29 Mohan M Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
KR20170135862A (ko) 2015-04-10 2017-12-08 켄달리온 테라퓨틱스 인코포레이티드 교체 가능한 앰플을 갖는 압전 디스펜서
EP3302704B1 (en) * 2015-06-01 2023-01-25 Metabolic Technologies, Inc. Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for decreasing fat mass
US10285963B2 (en) * 2015-06-08 2019-05-14 Horacio Astudillo de la Vega Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases
US10758504B2 (en) * 2015-09-16 2020-09-01 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
US11701336B2 (en) 2015-10-30 2023-07-18 Yasumasa Kato Method of determining composition effective for treating diabetes
JP6250196B2 (ja) * 2015-10-30 2017-12-20 恭正 加藤 糖尿病治療用組成物
CN106854643B (zh) * 2015-12-08 2021-01-26 台湾粒线体应用技术股份有限公司 植物萃取物用于提升粒线体活性的用途
US11406609B2 (en) 2016-01-21 2022-08-09 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for modulating autophagy and lipophagy
BR112018014920A2 (pt) * 2016-01-21 2018-12-18 Metabolic Tech Inc métodos de autofagia por modulação, de tratamento ou redução da probabilidade do início de uma condição mediada por autofagia, de tratamento, inibição, redução, diminuição, ou prevenção de um distúrbio relacionado à idade, de modulação da expressão ou atividade de pelo menos um fator de transcrição, de tratamento, prevenção, diminuição, inibição ou redução de uma condição patológica atribuível a um estado de excesso de nutriente, de promoção de longevidade por autofagia por modulação, de aumento da duração de tempo que um mamífero pode levar um estilo de vida ativo sem sofrer de condições associadas com envelhecimento e de prolongamento do período de saúde de um mamífero.
MX2018014407A (es) 2016-05-25 2019-02-21 Tsi Group Ltd Estabilizacion de formulaciones de acido beta-hidroxiisovalerico en capsulas de gel blando.
KR102412086B1 (ko) 2017-01-20 2022-06-22 켄달리온 테라퓨틱스 인코포레이티드 압전 유체 분배기
JP6895309B2 (ja) * 2017-05-11 2021-06-30 理研ビタミン株式会社 Ａｍｐｋ活性促進用組成物
CA3078966A1 (en) * 2017-10-26 2019-05-02 Vershalee SHUKLA Oral hypoglycemic agents as food additives and supplements
CN111712219A (zh) 2017-12-08 2020-09-25 科达莱昂治疗公司 流体递送对准系统
CN108324929B (zh) * 2018-03-09 2021-07-13 深圳市容大生物技术有限公司 一种减少体脂率及体脂反弹的组合物及其制备方法和应用
US20190314198A1 (en) 2018-04-12 2019-10-17 Kedalion Therapeutics, Inc. Topical Ocular Delivery Methods and Devices for Use in the Same
CN108642001B (zh) * 2018-05-08 2022-09-02 中国农业科学院北京畜牧兽医研究所 一种提高牛性控冻精体外受精能力的方法
EP3817696B8 (en) 2018-07-03 2024-12-11 Bausch + Lomb Ireland Limited Topical ocular delivery devices
US11701335B2 (en) * 2018-08-31 2023-07-18 Apr Applied Pharma Research S.A. Methods of normalizing amino acid metabolism
CN108837154B (zh) * 2018-08-31 2021-05-07 中国药科大学 一种细胞膜仿生脂蛋白靶向纳米递药系统的制备及应用
US10568352B1 (en) 2018-10-25 2020-02-25 Wiser Concepts, LLC Nutritional compositions and methods of treatment therewith
CN109517848A (zh) * 2018-11-01 2019-03-26 沈阳农业大学 具有抗灰葡萄孢菌活性的dhis的制备方法和应用
WO2020092877A1 (en) * 2018-11-02 2020-05-07 The Children's Hospital Of Philadelphia Modulation of mitochondrial biogenesis by increase in iron sulfur cluster activity
CN109521118A (zh) * 2018-12-18 2019-03-26 广西壮族自治区兽医研究所 一种同时测定桃金娘果中4种酚类物质的方法
US12097145B2 (en) 2019-03-06 2024-09-24 Bausch + Lomb Ireland Limited Vented multi-dose ocular fluid delivery system
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
US11219612B2 (en) 2019-06-11 2022-01-11 Dremcubed, Llc Nutraceutical formulation for unblocking receptors
WO2021096882A1 (en) * 2019-11-11 2021-05-20 Nusirt Sciences, Inc. Compositions, methods and kits for altering adipocytes
US20210145764A1 (en) * 2019-11-15 2021-05-20 Brigham Young University Compositions of cannabidiol (cbd), and/or polyphenols, and methods for the prevention and/or treatment of skin, muscle, nerve and inflammatory disorders, and biological factors and functions in mammals
WO2021158825A1 (en) * 2020-02-05 2021-08-12 DailyColors Health Inc. Compositions and methods for nutritional supplements
US11925577B2 (en) 2020-04-17 2024-03-12 Bausch + Lomb Ireland Limted Hydrodynamically actuated preservative free dispensing system
WO2021212038A1 (en) 2020-04-17 2021-10-21 Kedalion Therapeutics, Inc. Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
US12290472B2 (en) 2020-04-17 2025-05-06 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
CA3188423A1 (en) * 2020-09-04 2022-03-10 Francois-Pierre Martin Compositions and methods for providing health benefits in an animal
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN112836621B (zh) * 2021-01-29 2022-11-08 华东理工大学青岛创新研究院 一种植物细胞表型检测方法及系统
MX2023009722A (es) * 2021-02-21 2023-11-10 Pharma Cinq Llc Composiciones y compuestos para co-suministro de uridina y cetoleucina.
WO2023025101A1 (en) * 2021-08-26 2023-03-02 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Composition and method for enhancing mitochondrial biogenesis and activating pgc-1α
US20250122507A1 (en) * 2021-09-24 2025-04-17 The Trustees Of Indiana University Depletion of fndc5 reduces cancer induced muscle loss/cachexia
CN113698384B (zh) * 2021-10-26 2022-01-18 上海维京生物医药科技有限公司 阿格列汀没食子酸盐及其制备方法和应用
WO2025137462A1 (en) * 2023-12-21 2025-06-26 Numiera Therapeutics Inc. Combination therapy for cancer

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1007650A (en) 1911-05-13 1911-10-31 Wesley Ellis Belt-guide.
US3936527A (en) 1969-12-19 1976-02-03 Damon Corporation Treatment of pets
US3810994A (en) 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
NL7804375A (nl) 1977-05-16 1978-11-20 Ralston Purina Co Voedsel voor dieren.
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IE58246B1 (en) 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5087624A (en) 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US5886012A (en) 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
GB8919131D0 (en) 1989-08-23 1989-10-04 Riker Laboratories Inc Inhaler
JPH03219838A (ja) 1989-11-06 1991-09-27 Itochu Shiryo Kk 体脂肪の蓄積量を減少させる飼料
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5419283A (en) 1992-04-08 1995-05-30 Ciuffo Gatto S.R.L. Animal chew toy of starch material and degradable ethylene copolymer
JP3219838B2 (ja) 1992-05-12 2001-10-15 沖電気工業株式会社 半導体素子の製造方法
NZ256300A (en) * 1992-09-16 1997-06-24 Univ Iowa State Res Found Inc Administration of beta-hydroxy-beta-methyl butyric acid, or its convertible forms, to lower cholesterol levels
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
LU88369A1 (fr) 1993-07-12 1994-04-01 Michel Urso Prof Medecin Et Ch Acides aminés à chaînes ramifiées
US5339771A (en) 1993-09-15 1994-08-23 Axelrod Herbert R Animal chew toy containing animal meal
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5616569A (en) 1994-03-28 1997-04-01 The Iams Company Pet food product containing fermentable fibers and process for treating gastrointestinal disorders
US6048903A (en) 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
US5776913A (en) 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
EP0873754B1 (en) 1996-01-09 2003-07-30 Riken Amino acid compositions
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
EP0862863B9 (en) 1997-01-09 2009-08-12 Societe Des Produits Nestle S.A. Cereal product containing probiotics
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
IT1291113B1 (it) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6063414A (en) 1997-08-18 2000-05-16 Seal Rock Technologies Incorporated Combination container and dry pet food for increased shelf life, freshness, palatability, and nutritional value
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
JP2002513795A (ja) 1998-05-04 2002-05-14 ヨハネス ケーゼル アンドレアス モノマー、オリゴマーおよびポリマーのクネベナーゲル縮合生成物
US6387419B1 (en) 1998-06-02 2002-05-14 Biofiber-Damino A/S Piglet feeding method
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US6403142B1 (en) 1998-12-11 2002-06-11 Ralston Purina Company Hypoallergenic pet food
AU765909C (en) 1998-12-17 2004-09-23 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
EP1169322B8 (en) 1999-03-08 2006-09-13 Medicure Inc. Pyridoxal analogues for the treatment of disorders caused by a deficiency in vitamin b6
FR2790645B1 (fr) 1999-03-12 2001-06-08 Arkopharma Laboratoires Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols
AU7596100A (en) 1999-09-21 2001-04-24 Rutgers, The State University Resveratrol analogs for prevention of disease
US6527711B1 (en) 1999-10-18 2003-03-04 Bodymedia, Inc. Wearable human physiological data sensors and reporting system therefor
US6280779B1 (en) 1999-12-28 2001-08-28 Colgate-Palmolive Company Pet food for maintaining normal bowel health
CA2399319A1 (en) 2000-01-25 2001-08-16 Nathan D. Hamilton Nutritional supplements for aged pets
EG22407A (en) 2000-02-17 2003-01-29 Iams Company Method for improving bone modeling and chondrocyte functioning in growing canines
WO2005029242A2 (en) 2000-06-16 2005-03-31 Bodymedia, Inc. System for monitoring and managing body weight and other physiological conditions including iterative and personalized planning, intervention and reporting capability
US7261690B2 (en) 2000-06-16 2007-08-28 Bodymedia, Inc. Apparatus for monitoring health, wellness and fitness
US7689437B1 (en) 2000-06-16 2010-03-30 Bodymedia, Inc. System for monitoring health, wellness and fitness
US6605038B1 (en) 2000-06-16 2003-08-12 Bodymedia, Inc. System for monitoring health, wellness and fitness
US7285090B2 (en) 2000-06-16 2007-10-23 Bodymedia, Inc. Apparatus for detecting, receiving, deriving and displaying human physiological and contextual information
JP2002047699A (ja) 2000-07-31 2002-02-15 Toto Ltd 給水の配管システム
US20020165237A1 (en) 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
US6384087B1 (en) 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
TWI329516B (en) 2000-12-12 2010-09-01 Kaneka Corp Composition for preventing or ameliorating multiple risk factor syndromes and visceral fat-type obesity
WO2002052951A1 (en) 2000-12-29 2002-07-11 Martin Francis Gannon An animal food product
JP2004519241A (ja) 2001-03-09 2004-07-02 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 高齢化に伴う生理的障害を改善し寿命を延ばす組成物
US6338862B1 (en) 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
US6595929B2 (en) 2001-03-30 2003-07-22 Bodymedia, Inc. System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow
EP1435988A4 (en) 2001-10-19 2008-01-09 Pharmamar Sa IMPROVED USE OF ANTI-TUMORAL COMPOUND IN THE TREATMENT OF CANCER
EP1525323B1 (en) 2001-11-09 2015-01-21 Dana-Farber Cancer Institute, Inc. Pgc-1beta, a novel pgc-1 homologue and uses therefor
US20030181461A1 (en) 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US20030187055A1 (en) 2002-02-25 2003-10-02 Riker Donald K. Synergistic pharmaceutical combinations for treating obesity
US20040009216A1 (en) 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
CA2483464C (en) 2002-05-17 2011-12-20 Duke University Method for treating obesity
CN100453130C (zh) 2002-06-26 2009-01-21 精达制药公司 用于渗透性药物传递系统的最低顺应性和高容积效率的活塞
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
US7020508B2 (en) 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
US20050181097A1 (en) 2002-09-16 2005-08-18 Mars, Inc. Nutritionally complete pet food and method of feeding and manufacturing same
RU2335927C2 (ru) 2002-09-20 2008-10-20 Новартис Аг Обогащенные лейцином питательные композиции
US20050064070A1 (en) 2002-10-11 2005-03-24 Jeffrey Liebrecht Beverage compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US7744930B2 (en) 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
JP2004305201A (ja) 2002-11-27 2004-11-04 Hayashibara Biochem Lab Inc アクリルアミドの生成抑制方法とその用途
CN1504424A (zh) 2002-12-05 2004-06-16 上海金创投资管理有限公司 含亮氨酸婴儿饮用水
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
US7288570B2 (en) * 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
NZ542280A (en) * 2003-03-13 2008-08-29 Vector Usa Inc A film having a liquid absorbed therein
US20040186046A1 (en) 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
PL377614A1 (pl) 2003-03-18 2006-02-06 Novartis Ag Kompozycje zawierające kwasy tłuszczowe i aminokwasy
US7160565B2 (en) 2003-03-31 2007-01-09 Breakthru Products, Llc Hydration beverage and method of delivering nutrients
US20050042362A1 (en) 2003-04-02 2005-02-24 Clark Harry M. Pet food composition and method
WO2004100968A2 (en) 2003-05-14 2004-11-25 Indus Biotech Pvt. Ltd. A synergistic composition for the treatment of diabetes mellitus
US20070203083A1 (en) 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
FR2856407B1 (fr) 2003-06-19 2007-10-12 Inst Nat Sante Rech Med Procede de production d'une proteine recombinante d'interet et proteine produite
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
JP2005097273A (ja) 2003-08-19 2005-04-14 Toyo Shinyaku:Kk 運動能力向上組成物
EP1667579A4 (en) 2003-09-12 2008-06-11 Bodymedia Inc METHOD AND DEVICE FOR MEASURING CARDIAC PARAMETERS
CN100577027C (zh) 2003-11-03 2010-01-06 希尔氏宠物营养品公司 涂覆的宠物食品组合物
US7495101B2 (en) 2003-11-19 2009-02-24 Dsm Ip Assets B.V. Manufacture of vitamin B6
WO2005049006A1 (ja) * 2003-11-21 2005-06-02 Ajinomoto Co., Inc. 糖尿病治療剤
AU2004294986B2 (en) 2003-11-26 2010-09-09 Hill's Pet Nutrition, Inc. Method to reduce stool odor of companion animals
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20050171027A1 (en) * 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US20050215882A1 (en) 2004-03-23 2005-09-29 The Regents Of The University Of Michigan Noninvasive method to determine fat content of tissues using MRI
AU2005265031A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
EP1762234A4 (en) 2004-06-28 2010-05-05 Kao Corp AMPK AKTIVATOR
JP4785140B2 (ja) 2004-08-04 2011-10-05 国立大学法人東京海洋大学 脂質代謝調節作用を有する食品素材、健康食品、動物用飼料及び動物の飼育方法
AU2005277384B2 (en) 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
WO2006023975A2 (en) 2004-08-24 2006-03-02 Depuy Mitek, Inc. Expandable needle suture apparatus and associated handle assembly with rotational suture manipulation system
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8252314B2 (en) 2004-09-24 2012-08-28 Hill's Pet Nutrition, Inc. Hypoallergenic composition
WO2006057073A1 (ja) 2004-11-29 2006-06-01 Toyo Shinyaku Co., Ltd. 運動能力向上組成物
JPWO2006070873A1 (ja) * 2004-12-28 2008-06-12 味の素株式会社 アディポネクチン誘導剤又は分泌促進剤
WO2006079021A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20060165824A1 (en) 2005-01-26 2006-07-27 The Procter & Gamble Company Compositions, kits, and methods for enhancing gastrointestinal health
BRPI0606736A2 (pt) 2005-02-11 2009-07-21 Argenta Discovery Ltd combinação de compostos e esteróides de metilxantina para tratar doenças respiratórias crÈnicas
US20060188611A1 (en) 2005-02-18 2006-08-24 Emine Unlu Edible pet chew
JP2008535790A (ja) 2005-03-03 2008-09-04 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20100233312A9 (en) 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
CN101175501B (zh) 2005-05-13 2012-03-21 雀巢技术公司 由植物物种生产葡糖胺
EA013474B1 (ru) 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
JP2009500357A (ja) * 2005-07-07 2009-01-08 サートリス ファーマシューティカルズ， インコーポレイテッド 肥満、インスリン抵抗性障害およびミトコンドリア関連障害を処置または予防するための方法および関連する組成物
JP2007039367A (ja) 2005-08-02 2007-02-15 Kyoto Univ 細胞の分化を促進する組成物およびその利用
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
AU2006278504B2 (en) 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Imidazopyridine derivatives as sirtuin modulating agents
US20070077310A1 (en) 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
ATE508745T1 (de) 2005-11-30 2011-05-15 Novartis Pharma Gmbh Kombination umfassend mindestens eine aminosäure und einen pkr-inhibitor zur verwendung in der behandlung von muskelschwund
US20090136588A1 (en) 2005-12-02 2009-05-28 Hill's Pet Nutrition, Inc. Methods For Altering Food Intake, Modifying Nutrient Digestibility and Altering Stool Quality and/or Stool Frequency
US20070190171A1 (en) 2005-12-02 2007-08-16 Yamka Ryan M Methods for Altering Stool Quality and/or Stool Frequency
JPWO2007069744A1 (ja) * 2005-12-16 2009-05-28 味の素株式会社 メタボリックシンドローム予防・改善用組成物
BRPI0706448A2 (pt) 2006-01-10 2011-03-29 Hills Pet Nutrition Inc método, composição e kit para promover perda de gordura em um animal adulto, meio para comunicar informação sobre ou instruções para usar uma dieta, e, uso de lisina
KR20080108487A (ko) 2006-02-28 2008-12-15 트르스티스 오브 보스톤 유니버시티 대사 조절인자 및 그의 용도
JP5222482B2 (ja) * 2006-04-07 2013-06-26 花王株式会社 脂肪分解促進剤
DE102006016903A1 (de) 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalator
WO2007128461A1 (en) 2006-05-10 2007-11-15 Dsm Ip Assets B.V. Animal food composition comprising genistein and polyunsaturated fatty acids
JP2007306851A (ja) 2006-05-18 2007-11-29 仁 ▲吉▼井 食塩組成物およびその製造方法
US20070286909A1 (en) 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
US20090291958A1 (en) 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
CA2658394C (en) 2006-07-12 2016-08-16 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
ITRM20060427A1 (it) 2006-08-04 2008-02-05 Nuraging Biotech S R L Composizioni antiossidanti comprendenti estratti di rosmarino e mirto
JP5507802B2 (ja) 2006-08-10 2014-05-28 花王株式会社 筋肉老化抑制剤
US8703174B2 (en) 2006-09-15 2014-04-22 I Did It Inc Joint preserving nutritional vitamin, mineral and herbal pet supplement
US20080102137A1 (en) 2006-10-31 2008-05-01 Guffey Manning V R Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
AU2007341981A1 (en) * 2006-12-29 2008-07-10 The Salk Institute For Biological Studies Methods for enhancing exercise performance
BRPI0806774A2 (pt) 2007-01-16 2011-09-13 Ipintl Llc composição para tratamento de sìndrome metabólica
US20080319786A1 (en) 2007-02-16 2008-12-25 Stivoric John M Publishing and insurance applications of lifeotypes
CA2678807C (en) 2007-02-23 2012-07-17 Hill's Pet Nutrition, Inc. Compositions and methods for controlling the weight of animals
WO2008115563A1 (en) 2007-03-19 2008-09-25 University Of Florida Research Foundation, Inc. Liquid nutrient composition for improving performance
US7850997B2 (en) * 2007-03-21 2010-12-14 Tim Romero Dietary compositions and methods of enhancing lean body mass and exercise performance
US20080242727A1 (en) 2007-03-27 2008-10-02 Tim Romero Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass
WO2008119070A1 (en) 2007-03-28 2008-10-02 Trustees Of Boston University Methods of treatment using sirt modulators and compositions containing sirt1 modulators
US20080268038A1 (en) 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
JP2010526781A (ja) 2007-04-30 2010-08-05 アボット・ラボラトリーズ ジアシルグリセロールｏ−アシル転移酵素１型酵素の阻害剤
JPWO2008143182A1 (ja) 2007-05-17 2010-08-05 株式会社カネカ 甘草ポリフェノールを含有する組成物
JP5121308B2 (ja) * 2007-05-28 2013-01-16 ハウスウェルネスフーズ株式会社 メタボリックシンドロームの予防、改善または治療組成物
US20100204204A1 (en) 2007-06-06 2010-08-12 University Of South Florida Nutraceutical co-crystal compositions
WO2008157537A2 (en) 2007-06-19 2008-12-24 Ironwood Pharmaceuticals, Inc Compositions and methods of use for treating or preventing lipid related disorders
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US7989007B2 (en) 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
WO2009003798A1 (en) 2007-07-05 2009-01-08 Unilever N.V. Food composition comprising trans-resveratrol and its use to control blood pressure
EP2170338A2 (en) 2007-07-06 2010-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna-pkcs modulates energy regulation and brain function
US8529965B2 (en) 2007-07-09 2013-09-10 Hill's Pet Nutrition, Inc. Compositions and methods for altering stool quality in an animal
JP5550077B2 (ja) 2007-09-07 2014-07-16 ナイキ インターナショナル リミテッド 運動機能性を有する装着可能な装置アセンブリ
US7820618B2 (en) * 2007-10-04 2010-10-26 Northern Innovations and Formulations Energy status of an individual by enhanced usage of an endogenous fuel source
US20090104312A1 (en) 2007-10-22 2009-04-23 Kamarei A Reza Neutralized juice-based beverages and method of making same
EP2214698A2 (en) 2007-10-23 2010-08-11 President and Fellows of Harvard College Use of compounds activating sirt-3 for mimicking exercise
US20090110674A1 (en) * 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
US20090156648A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (HICA)
AU2008345571B2 (en) 2007-12-21 2011-10-13 Hill's Pet Nutrition, Inc. Pet food composition
US8716249B2 (en) 2008-01-31 2014-05-06 Energy Light Llc Compositions and methods for improving cardiovascular health
MY158994A (en) 2008-02-04 2016-11-30 Mercury Therapeutics Inc Ampk modulators
CN106021913B (zh) 2008-03-03 2019-08-09 耐克创新有限合伙公司 交互式运动设备系统及方法
BRPI0908718A2 (pt) 2008-03-17 2019-09-24 Procter & Gamble sistema de dosagem personalizável pelo usuário
JP5645809B2 (ja) 2008-04-02 2014-12-24 ナイキ イノベイト セー． フェー． 運動用機能を有するウェアラブルデバイスアセンブリ
KR20110039249A (ko) 2008-07-07 2011-04-15 모치다 세이야쿠 가부시키가이샤 지질 이상증의 개선 또는 치료약
JP2011528557A (ja) 2008-07-18 2011-11-24 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 過体重動物と関連する障害を治療するための組成物および方法
US20100021573A1 (en) 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
CN102300569A (zh) 2008-08-15 2011-12-28 雀巢产品技术援助有限公司 促进能量代谢的方法
FR2938732B1 (fr) * 2008-11-21 2011-04-01 Holymark Composition nutritive pour sportif, en particulier pour pratiquant d'une activite physique superieure a une heure.
CA2745376A1 (en) 2008-12-01 2010-06-10 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
US20120035105A1 (en) 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
EP2425303B1 (en) 2009-04-26 2019-01-16 NIKE Innovate C.V. Gps features and functionality in an athletic watch system
US20100303968A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food in the Form of a Coated Kibble
US20100303966A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food in the Form of a Coated Kibble
US20100303967A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food Having Improved Animal Preference
EP2448413A4 (en) 2009-07-01 2013-02-13 Magceutics Inc SLOW RELEASE MAGNESIUM COMPOSITION AND USES THEREOF
EP2451295A1 (en) 2009-07-21 2012-05-16 Hill's Pet Nutrition, Inc. Companion animal nutrition system
US20110027417A1 (en) 2009-07-31 2011-02-03 Patrick Joseph Corrigan Process for Dusting Animal Food
US8691303B2 (en) 2009-07-31 2014-04-08 The Iams Company Dusted animal food
US20110064720A1 (en) 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
EP2477620A1 (en) 2009-09-18 2012-07-25 Polifenoles Naturales, S.L. Method of slowing the aging process by activating sirtuin enzymes with a combination of fucoxanthin and punicic acid
WO2011051974A1 (en) * 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
CN102053946B (zh) 2009-10-30 2014-05-28 国际商业机器公司 多核系统中处理请求的数据处理方法、设备和系统
US8173181B2 (en) 2009-11-09 2012-05-08 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
EP2512236B1 (en) * 2009-12-18 2016-10-19 Metabolic Technologies, Inc. Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)
AU2010336985B2 (en) 2009-12-29 2013-09-19 Hill's Pet Nutrition, Inc. Compositions including pyruvate for companion animals and methods of use thereof
MX340938B (es) 2010-01-06 2016-08-01 Nestec Sa Regimenes dieteticos utiles para imitar la restriccion calorica.
US20110208153A1 (en) 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
US8663716B2 (en) 2010-04-28 2014-03-04 Nihon Pharmaceutical Co., Ltd. Composition for treatment of aesthenopia
US20120058088A1 (en) 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
CN102077936B (zh) 2010-09-20 2013-04-24 王强 一种糖尿病患者专用的海洋特膳食品
US9167991B2 (en) 2010-09-30 2015-10-27 Fitbit, Inc. Portable monitoring devices and methods of operating same
AU2012204162B2 (en) 2011-01-07 2017-04-20 Anji Pharmaceuticals Inc. Chemosensory receptor ligand-based therapies
WO2012097064A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
EP3466418A1 (en) * 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
AU2012299126B2 (en) 2011-08-19 2016-05-26 Musclepharm Corporation Compositions and methods for use in promoting lean body mass
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
KR101409330B1 (ko) 2012-05-11 2014-06-18 안국약품 주식회사 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
CN108452311A (zh) 2012-11-13 2018-08-28 纽斯尔特科学公司 用于增强能量代谢的组合物和方法
WO2014113404A1 (en) 2013-01-15 2014-07-24 Nusirt Sciences, Inc. Treating pulmonary conditions
AU2014238377A1 (en) 2013-03-15 2015-09-10 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators
WO2014152016A1 (en) 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
WO2015053379A1 (en) 2013-10-07 2015-04-16 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
MX2016011063A (es) 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
WO2016049236A1 (en) 2014-09-24 2016-03-31 Nusirt Sciences, Inc. Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
WO2017040407A1 (en) 2015-09-01 2017-03-09 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash)

Also Published As

Publication number Publication date
IL230467A0 (en) 2014-03-31
EP2731599A4 (en) 2015-04-08
US9351967B2 (en) 2016-05-31
CN108261547A (zh) 2018-07-10
US20130017284A1 (en) 2013-01-17
US10383837B2 (en) 2019-08-20
US20190224152A1 (en) 2019-07-25
RU2014105552A (ru) 2015-08-27
CN103889411A (zh) 2014-06-25
US9855235B2 (en) 2018-01-02
US9198883B1 (en) 2015-12-01
US20160113915A1 (en) 2016-04-28
US20130017283A1 (en) 2013-01-17
US8617886B2 (en) 2013-12-31
EP2731599B1 (en) 2018-10-31
CN103889411B (zh) 2018-03-16
HK1198925A1 (en) 2015-06-19
RU2017129378A (ru) 2019-02-04
AU2017213477A1 (en) 2017-08-31
SG10201609673QA (en) 2017-01-27
US9682053B2 (en) 2017-06-20
PH12014500198A1 (en) 2017-02-10
JP2014520864A (ja) 2014-08-25
CN108114285A (zh) 2018-06-05
AU2012284267B2 (en) 2017-06-29
RU2631597C2 (ru) 2017-09-25
EP3466418A1 (en) 2019-04-10
CA2841748C (en) 2021-06-15
HK1250656A1 (zh) 2019-01-11
AU2012284267A1 (en) 2014-01-30
BR112014000895A2 (pt) 2019-08-06
JP2017160258A (ja) 2017-09-14
WO2013012760A1 (en) 2013-01-24
KR20140054066A (ko) 2014-05-08
US20140148488A1 (en) 2014-05-29
ZA201400553B (en) 2018-07-25
IL230467B (en) 2020-07-30
CA2841748A1 (en) 2013-01-24
EP2731599A1 (en) 2014-05-21
MX2014000419A (es) 2014-09-22
US20160338983A1 (en) 2016-11-24
US10076507B1 (en) 2018-09-18
US20150342914A1 (en) 2015-12-03
US9072692B2 (en) 2015-07-07
HK1251146A1 (zh) 2019-01-25
US8623924B2 (en) 2014-01-07
US20170312240A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
JP6158801B2 (ja) 代謝経路を変調させるための組成物および方法
JP6469015B2 (ja) エネルギー代謝を増大させるための組成物および方法
JP2017506651A (ja) 脂肪肝の低減または予防のための組成物および方法
HK1198925B (en) Compositions and methods for modulating metabolic pathways

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150710

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170530

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170608

R150 Certificate of patent or registration of utility model

Ref document number: 6158801

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250